Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden
(2020) In Läkartidningen 117.- Abstract
Alzheimer's disease is the most common cause of dementia. As many as 250,000 people in Sweden will have a dementia disease in 2050. The »amyloid cascade hypothesis« is a common model which explains how β-amyloid affects the function of the nerve cells. Alzheimer's disease has a long-lasting course and can present in typical and atypical forms. CSF analyses for »core AD CSF biomarkers« and synaptic proteins have been available for clinical diagnostics. PET scanning can detect either β-amyloid or tau aggregates in the brain of living humans. Current Alzheimer's disease therapy is based on two classes of cognition-enhancing drugs: acetylcholinesterase inhibitor and NMDA-receptor antagonist, which delays cognitive decline in most patients.... (More)
Alzheimer's disease is the most common cause of dementia. As many as 250,000 people in Sweden will have a dementia disease in 2050. The »amyloid cascade hypothesis« is a common model which explains how β-amyloid affects the function of the nerve cells. Alzheimer's disease has a long-lasting course and can present in typical and atypical forms. CSF analyses for »core AD CSF biomarkers« and synaptic proteins have been available for clinical diagnostics. PET scanning can detect either β-amyloid or tau aggregates in the brain of living humans. Current Alzheimer's disease therapy is based on two classes of cognition-enhancing drugs: acetylcholinesterase inhibitor and NMDA-receptor antagonist, which delays cognitive decline in most patients. The latest clinical development of potential therapy for Alzheimer's is active or passive immunotherapy against brain β-amyloid and tau, where several studies have shown varying but promising treatment effects. Non-pharmacological interventions in patients with AD aim to delay the loss of mental abilities, helping people to be independent in everyday life for as long as possible, and to increase their well-being and quality of life.
(Less)
- author
- Bogdanovic, Nenad
; Hansson, Oskar
LU
; Zetterberg, Henrik LU ; Basun, Hans ; Ingelsson, Martin ; Lannfelt, Lars and Blennow, Kaj LU
- organization
- alternative title
- Alzheimer's disease - the most common cause of dementia
- publishing date
- 2020-03-09
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Läkartidningen
- volume
- 117
- article number
- FZHM
- publisher
- Swedish Medical Association
- external identifiers
-
- scopus:85081945477
- pmid:32154904
- ISSN
- 0023-7205
- language
- Swedish
- LU publication?
- yes
- id
- da74600a-c228-464d-a33d-154ee3aa8230
- alternative location
- https://lakartidningen.se/klinik-och-vetenskap-1/artiklar-1/temaartikel/2020/03/alzheimers-sjukdom-diagnostik-och-behandling-i-dag-och-i-framtiden/
- date added to LUP
- 2021-01-12 10:42:23
- date last changed
- 2024-06-27 06:51:19
@article{da74600a-c228-464d-a33d-154ee3aa8230, abstract = {{<p>Alzheimer's disease is the most common cause of dementia. As many as 250,000 people in Sweden will have a dementia disease in 2050. The »amyloid cascade hypothesis« is a common model which explains how β-amyloid affects the function of the nerve cells. Alzheimer's disease has a long-lasting course and can present in typical and atypical forms. CSF analyses for »core AD CSF biomarkers« and synaptic proteins have been available for clinical diagnostics. PET scanning can detect either β-amyloid or tau aggregates in the brain of living humans. Current Alzheimer's disease therapy is based on two classes of cognition-enhancing drugs: acetylcholinesterase inhibitor and NMDA-receptor antagonist, which delays cognitive decline in most patients. The latest clinical development of potential therapy for Alzheimer's is active or passive immunotherapy against brain β-amyloid and tau, where several studies have shown varying but promising treatment effects. Non-pharmacological interventions in patients with AD aim to delay the loss of mental abilities, helping people to be independent in everyday life for as long as possible, and to increase their well-being and quality of life.</p>}}, author = {{Bogdanovic, Nenad and Hansson, Oskar and Zetterberg, Henrik and Basun, Hans and Ingelsson, Martin and Lannfelt, Lars and Blennow, Kaj}}, issn = {{0023-7205}}, language = {{swe}}, month = {{03}}, publisher = {{Swedish Medical Association}}, series = {{Läkartidningen}}, title = {{Alzheimers sjukdom – diagnostik och behandling i dag och i framtiden}}, url = {{https://lakartidningen.se/klinik-och-vetenskap-1/artiklar-1/temaartikel/2020/03/alzheimers-sjukdom-diagnostik-och-behandling-i-dag-och-i-framtiden/}}, volume = {{117}}, year = {{2020}}, }